<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291615</url>
  </required_header>
  <id_info>
    <org_study_id>KHBO1003</org_study_id>
    <secondary_id>UMIN000004682</secondary_id>
    <nct_id>NCT01291615</nct_id>
  </id_info>
  <brief_title>Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer</brief_title>
  <official_title>Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansai Hepatobiliary Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansai Hepatobiliary Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To decide maximum tolerated dose and/or recommended dose of Gemcitabine or S-1 adjuvant
      therapy after hemihepatectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no standard adjuvant therapy after liver hemi-hepatectomy due to bile duct cancer,
      because of high surgical morbidity ratio and high adverse event ratio of adjuvant therapy.
      For example, our preliminary results showed that regular gemcitabine administration
      (1000mg/m2, day1, 8, 15 every 4 weeks) after hemihepatectomy was too toxic and induced severe
      leukocytopenia and/or thrombocytopenia. Herein, we planned this study to decide more safety
      adjuvant protocol(recommend dose) for gemcitabine and S-1 after hemihepatectomy using
      continual reassessment method analysis. In this study, we decided that tolerable ratio of
      dose-limiting toxicity would be less than 10%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency in adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>The purpose of this study is to decide maximum tolerated dose and recommended dose. Recommended dose is a dose which would induce dose-limiting toxicity in 10% of participants. This will be calculated by continual reassessment method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks</description>
    <arm_group_label>Gemcitabine group</arm_group_label>
    <other_name>gemzer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.</description>
    <arm_group_label>S-1 group</arm_group_label>
    <other_name>TS-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Biliary tract cancer (&gt;= UICC Stage IB)

          2. R0 or R1 resection due to biliary tract cancer (BTC)

          3. ECOG performance status must be 0 or 1

          4. The patient underwent no other treatment than surgery for BTC

          5. Neutrophil must be over 1500/μl, platelet must be over 100,000/μl, AST and ALT must be
             less than five times the normal limit, total bilirubin must be less than three times
             the normal limit, and creatinin must be less than 1.2 mg/dl.

          6. The patient can intake drugs per os.

          7. From 4 to 12 weeks after the surgery

          8. Written informed consent

        Exclusion Criteria:

          1. Existence of active double cancer

          2. The patient suffered from severe drug allergy

          3. Sever complications (interstitial pneumonia, heart failure, renal failure, liver
             failure, ileus, incontrollable diabetes mellitus, and so on)

          4. Any active infections exist.

          5. Pregnancy

          6. Severe mental disorder

          7. Others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Nagano, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Osaka University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University, Graduate School of Medicine</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, Takemura S, Kubo S, Yanagimoto H, Toyokawa H, Tsuji A, Terajima H, Morita S, Ioka T. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol. 2014 Oct;74(4):699-709. doi: 10.1007/s00280-014-2543-4. Epub 2014 Jul 30.</citation>
    <PMID>25074036</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>February 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>October 21, 2014</last_update_submitted>
  <last_update_submitted_qc>October 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

